Griffith University researchers are moving closer to providing independence to people living with spinal cord injury through an innovative, world-first nerve cell bridge therapy combined with patient-centred rehabilitation.

Losing the ability to walk is a frightening thought – but have you ever considered the many other effects of spinal cord injury?

“If you have a spinal cord injury and you’re paralysed, you’re paralysed for life. But it’s not just about walking – paralysis can lead to broader loss of movement, feeling, and autonomic bowel, bladder and sexual functions. People living with spinal cord injury are also impacted by depression, loss of independence, and reduced involvement in employment and education,” said Professor James St John. “We need a treatment that gives people living with spinal cord injury their bodies back.”

Professor James St John, Dr Mo Chen, Dr Mariyam Murtaza and their team of more than 30 researchers at the Clem Jones Centre for Neurobiology and Stem Cell Research, Griffith University, are on the verge of a human Phase 1/2a clinical trial for treating spinal cord injury to be delivered in Queensland, Australia.

They have developed an innovative, world-first nerve bridge therapy that uses olfactory ensheathing cells obtained from the patient’s own nose. As olfactory nerve cells within the nose interact with the external environment to detect smells and send signals to the brain, they require the ability to regenerate if damaged.

Olfactory ensheathing cells are essential to this process and importantly, they can also regenerate damaged nerves elsewhere in the body.

The team found that these cells can be formulated into three-dimensional nerve bridges that can easily be handled by surgeons for transplantation into a site of injury to create functional motor and sensory connections.

The nerve bridge aims to alleviate the negative health, economic, and social impacts affecting an estimated 20 million people globally who live with spinal cord injury.

In Australia alone, the lifetime cost of care and lost economic activity for someone with quadriplegia is $9 million and the total current cost to the community for all spinal cord injuries exceeds $3 billion annually.

Professor St John and his team have used a co-design approach across their research, including working with a Spinal Cord Injury National Consumer Research Panel consisting of eight people from around Australia living with spinal cord injury. This has allowed them to go beyond the laboratory to set their work up for success.

In treating spinal cord injury, patients need access to effective rehabilitation programs that complement cell transplantation treatments and maximise their effectiveness. In developing such programs, you need to talk directly with people who live with spinal cord injury and their carers to ensure you meet their expectations and needs and so they feel comfortable opting into the therapy.

Professor James St John, Clem Jones Centre for Neurobiology and Stem Cell Research, Griffith University.

To de-risk the upcoming human Phase 1/2a clinical trial, two intensive rehabilitation clinical trials were run by partner organisation Making Strides with people living with spinal cord injury who were either experienced or inexperienced with rehabilitation.

Both trials were very successful – all participants completed the program and there were identifiable improvements in their physical and psycho-social health. After the program one assessor noted that participants were much more confident and happier and were looking forward to continuing rehabilitation in their own time.

The upcoming human Phase 1/2a clinical trial will look at how participants living with chronic spinal cord injury respond to both the nerve bridge transplantation and rehabilitation program.

“For too long there has been no hope for people, and now this incredible team of medical researchers are starting to make changes that we’ve never seen before,” said Perry Cross AM, Perry Cross Spinal Research Foundation.

Since the opening of the Clem Jones Centre for Neurobiology and Stem Cell Research in 2016, the Centre’s major funders have included the Clem Jones Group, Perry Cross Spinal Research Foundation, the Queensland Government and the Motor Accident Insurance Commission (MAIC).

This funding also supports the team’s wider research program looking at neurodegeneration (particularly Alzheimer’s disease) and nerve repair.

“Our latest round of funding will also allow us to expand the nerve bridge technology to a wider range of nervous system injuries including peripheral nerve and brain injuries,” said Professor St John.

“We can’t underestimate the independence and self-worth that we can give back to people by reversing spinal cord, nervous system and brain injuries. Restoring movements, sensation and autonomic functions, such as having control of their bladders or being able to move their fingers are significant steps forward for people living with such injuries.”

The Clem Jones Centre for Neurobiology and Stem Cell Research is seeking philanthropic and general donations and investments to progress their work. If you would like to help facilitate their research, please find more information here:

Support the Clem Jones Centre for Neurobiology and Stem Cell Research

To learn more about Professor St John's research and his contact details please go to:

Griffith Experts

Banner image courtesy of Making Strides

This research impact story is dedicated to the late Professor Emeritus Alan Mackay-Sim AM

For more than 30 years, Professor Emeritus Alan Mackay-Sim AM made a profound contribution as a world-leading scientist in the use of patient-derived stem cells.

His research opened new possibilities in developing disease-modifying drugs for neurological conditions such as schizophrenia, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, ataxia telangiectasia, and Hereditary Spastic Paraplegia.

Professor Emeritus Mackay-Sim was also integral in the world-first clinical trials that demonstrated the safety of olfactory cell biopsy, culture, and transplantation into the injury site of people living with spinal cord injury.

His groundbreaking work is continued by Professor St John and his colleagues.

Vale Professor Emeritus Alan Mackay-Sim AM – 1951-2023

3 Good Health and Well-being 17 Partnerships for the goals

Sustainable Development Goals

Griffith University is aligned with the United Nation's Sustainable Development Goals ( SDGs ) and is committed to advancing knowledge, innovation, and practices that promote holistic health and well-being while fostering partnerships for the goals.

Discover more of Griffith's impact stories across diverse disciplines on our Impact Website